Mineralys Therapeutics, Inc. (MLYS) SEC Filings & Earnings Calls

FDA approval risk

“The Maturity Date is subject to acceleration to June 30, 2028 if the Tranche B Approval Condition is not satisfied on or before September 30, 2027.” · word for word

Debt covenant risk

“The Loan Agreement contains financial covenants, including a minimum liquidity requirement and...a minimum trailing twelve-month consolidated net product revenue covenant.” · word for word

Clinical trial failure risk

“After four weeks of treatment, lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on the apnea-hypopnea index, the primary endpoint.” · word for word

Regulatory approval risk; PDUFA date Dec 22, 2026.

“PDUFA target date of December 22, 2026 for lorundrostat.” · word for word

Commercial execution risk; need to build sales organization.

“The Company expects to have the sales organization established in advance of the anticipated PDUFA target date.” · word for word

High cash burn; net loss increasing.

“Net loss was $34.5 million for the three months ended June 30, 2026, compared to $22.0 million for the three months ended June 30, 2025.”

Dilution risk from equity offering.

“5.66M new shares issued, diluting existing holders.”

Increased debt burden and milestone obligations.

“Up to $500M in term loans, plus milestone payments up to $255M.”

Regulatory approval uncertainty

“The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat.” · word for word

No approved products or revenue

“We are a biopharmaceutical company focused on developing medicines... no mention of approved products or revenue in the filing.” · word for word

Regulatory approval risk for lorundrostat; PDUFA date Dec 22, 2026.

“NDA accepted; PDUFA target date December 22, 2026.”

Pre-commercial spending increases G&A; potential cash burn acceleration.

“G&A expenses increased to $21.0M from $6.6M.”

Dependence on equity financing

“In September 2025, we entered into an underwriting agreement with certain underwriters, pursuant to which we sold to investors in a public offering 11,274,509 shares of our common stock at a price of $25.50 per share for aggregate net proceeds of approximately $269.6 million.” · word for word

Clinical-stage biotech risk

“The corporate goals the compensation committee established for 2025 and 2024 related to clinical, nonclinical, regulatory, drug and product manufacturing, business development, and financing milestones.” · word for word

Single product candidate dependency

“Our future performance at this time is entirely dependent on the success of our only product candidate, lorundrostat.” · word for word

Regulatory approval uncertainty

“If we are unable to obtain regulatory approval, and ultimately commercialize lorundrostat, or experience significant delays in doing so, our business will be materially harmed.” · word for word

Need for additional capital

“We will need substantial additional funds to pursue our business objectives, which may not be available on acceptable terms, or at all.” · word for word

Competition from existing and pipeline therapies

“We face significant competition, and if our competitors develop and commercialize technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective, safer, or less expensive than lorundrostat and any future product candidates we develop, our business and our ability to develop and successfully commerci” · word for word

Explore-OSA Phase 2 trial missed primary endpoint, raising uncertainty about lorundrostat's efficacy in OSA.

“lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on AHI, the primary endpoint” · word for word

Reliance on single drug candidate lorundrostat; any regulatory or clinical setback could significantly impact company.

“Company is focused on lorundrostat; NDA acceptance is key but approval not guaranteed.”

Phase 2 Explore-OSA trial failed primary endpoint; regulatory risk for hypertension NDA

“Explore-OSA did not demonstrate clinically meaningful difference on AHI; NDA under FDA review”

Clinical and regulatory risk; NDA review outcome uncertain

“NDA filed but FDA review pending; clinical trial results pending”

No approved products or revenue

“We do not have any products approved for sale, have not generated any revenue, and have incurred net losses since our inception.” · word for word

Regulatory approval uncertainty

“We plan to submit an NDA in late 2025 or during the first quarter of 2026.” · word for word

Clinical and regulatory risk for lorundrostat NDA.

“NDA submission planned, but approval not guaranteed.”